Diazoxide choline CR is under clinical development by Soleno Therapeutics and currently in Pre-Registration for Prader-Willi Syndrome (PWS). According to GlobalData, Pre-Registration drugs for Prader-Willi Syndrome (PWS) have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Marketed. GlobalData’s report assesses how Diazoxide choline CR’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Diazoxide choline CR overview
Diazoxide choline controlled release (DCCR) is under development for the treatment of Prader-Willi syndrome, hypothalamic and SH2B1 deficiency obesity, hyperphagic obesity. The drug candidate is formulated as a tablet and administered through oral route. It targets ATP sensitive inward rectifier potassium channel 11. It is a new chemical entity (NCE). The drug candidate was also under development for the treatment of Smith-Magenis syndrome, hypertriglyceridemia and dyslipidemia.
Soleno Therapeutics overview
Soleno Therapeutics (Soleno) focuses on the development of novel therapeutics for the treatment of rare diseases. The company’s lead products includes Diazoxide Choline Controlled Release (DCCR), is a tablet that include crystalline salt formulation of diazoxide. Soleno provides cosense which is a portable device that is used to measure carbon monoxide in exhaled breath. The company offers various solutions to properly diagnose, monitor and care for children. It markets its products through its network of distributors. Soleno is headquartered in Redwood City, California, the US.
For a complete picture of Diazoxide choline CR’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
